{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6q6M4LDA","lastupdate":"2022-11-03T00:00:00.000Z","update_date":"2022-11-03T00:00:00.000Z","lastModified":"Dec 24, 2024","active":1,"confidence_score":92,"confidence_score_reason":"markets, not claimed","urlname":"endospan","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$HRpWY90znSJ9krXJ77BglCFouu9thXgVbEpi4qHkyyhD9Yn36NglzE","name":"EndoSpan","oneliner":"Stent Graft Systems for Aneurysms and Dissections","registrar":"514172931","website":"https://www.endospan.com","careerspage":"https://www.endospan.com/careers","founded_month":8,"founded_year":2008,"formernames":[],"sociallinks":{"twitter":"https://www.twitter.com/EndospanLtd","youtube":"https://www.youtube.com/channel/UCTUkswGXbpkg0Sskz_GcgMw","facebook":"https://www.facebook.com/EndospanLtd/timeline","linkedin":"https://www.linkedin.com/company/17988904","instagram":""},"social":["https://www.twitter.com/EndospanLtd","https://www.youtube.com/channel/UCTUkswGXbpkg0Sskz_GcgMw","https://www.facebook.com/EndospanLtd/timeline","https://www.linkedin.com/company/17988904"],"flattenedsociallinks":"https://www.twitter.com/EndospanLtd|https://www.youtube.com/channel/UCTUkswGXbpkg0Sskz_GcgMw|https://www.facebook.com/EndospanLtd/timeline|https://www.linkedin.com/company/17988904","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"51-200","employees_exact":59,"patent":1,"raised":20000000,"stage":"B","public_stage":"B","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"Endospan develops low-profile stent graft systems for treating aneurysms and dissections throughout the aorta, including infrarenal, visceral, and thoracic. Endospan helps make the treatment of aneurysms, dissections, and aortic lesions simpler and less invasive, making it a suitable choice for patients with limited treatment options.\r\n\r\nEndospan's HORIZON system can be used in a single-sided approach, generally shortening and simplifying EVAR procedures. It is especially useful for patients for whom a two-sided approach is physically impossible because of occlusions, natural anatomical contraindications, or other pathologies arising from prior surgical intervention.\r\n\r\nThe company's NEXUS is an aortic stent graft system whose modular approach offers a minimally invasive endovascular solution for patients diagnosed with an aneurysm in the ascending aorta or the aortic arch. \r\n\r\nIn March 2019, Endospan announced that it received the CE Mark for its Nexus stent graft system to be used for branched endovascular repair in the aortic arch. In April 2020, the Nexus aortic arch stent graft system received FDA breakthrough device designation.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97297884490","country":null,"address":{"israeli":[{"id":"56ae559d-5092-4a05-8fba-affaeb7bb159","city":"Herzliya","type":null,"address":"Maskit Street 4, Herzliyya, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"iKAyY23eiA8fK4tiHu1a1mGgxGSY3rxAQlwavrHPz4Jc6STTRg7Wre","date":"Jul 1, 2024","link":"https://www.prnewswire.co.uk/news-releases/endospan-receives-additional-25m-from-artivion-for-nexus-fda-approval-path-302188027.html","source":"www.prnewswire.co.uk","visible":1,"analysis":{"tags":"FDA approval","company":"Endospan Ltd","layoffs":null,"summary":"Endospan Ltd, an Israeli-based company, has announced an agreement with Artivion, Inc for additional loans of up to $25 million to support the FDA approval process for its NEXUS Stent Graft System. This partnership aims to advance the IDE study with the FDA, offering minimally invasive solutions for patients with aortic arch disease. The NEXUS system, already CE-marked in Europe, is the first approved branched endovascular system for treating aortic arch disease, addressing a significant market opportunity. The TRIOMPHE IDE Study is currently enrolling patients to evaluate the safety and effectiveness of NEXUS. The collaboration with Artivion is expected to enhance Endospans ability to provide innovative solutions for complex aortic conditions.","partners":"Artivion, Inc","customers":null,"investors":"Artivion, Inc","confidence":10,"key_topics":["NEXUS","FDA approval","aortic arch","minimally invasive","Endospan"],"date_of_event":"July 2, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$25M","structured_issues":["Investment","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"B2WfMiMq8jTIaFc4TgBvYduM2w2r2nxJ7aqc0cyH7LfhKALyv8pd7u","news_summary":"ENDOSPAN RECEIVES ADDITIONAL $25M FROM ARTIVION FOR NEXUS FDA APPROVAL PATH","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ka5Ft6W8htzcuXHtrigaLiek6imFmiIWjpuWW3yff3CuRgM84kp6li","date":"Nov 1, 2021","link":"https://www.businesswire.com/news/home/20211101005059/en/Endospan-Reports-Landmark-Publication-on-the-Initial-Experience-With-the-NEXUS%E2%84%A2-Aortic-Arch-Stent-Graft-System","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"TNjv6B9AFjjFKJ70mqrRl8kd4rJgg835JjJoWVvqXVZNZl7rL307Vw","news_summary":"Endospan Reports Landmark Publication on the Initial Experience With the NEXUS™ Aortic Arch Stent Graft System","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"d844baa2-e8c7-4c86-a4a0-25698a6e82dc","date":"Jan 12, 2021","link":"https://www.businesswire.com/news/home/20210112005067/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"EU2xDPLQmfi4nmvc3z14wMHf8I7DavSWa6ZlPQHc4zv9cU6xiWYNvG","news_summary":"Endospan Enrolls First Patient in the TRIOMPHE IDE Study","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"b2992d29-b42c-4f13-b34b-e5c208be8460","date":"Aug 17, 2020","link":"https://www.businesswire.com/news/home/20200817005127/en/Endospan-Receives-FDA-IDE-Approval-Initiate-Pivotal","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"OETOYECe6kudkOHr4J8t9TXZUS5fZ27RrW5Aazo5hFubUVWgHxLm23","news_summary":"Endospan Receives FDA IDE Approval to Initiate a Pivotal Study of the NEXUS™ Aortic Arch Stent Graft System","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"b26c7fa5-5747-4a06-8aa9-1ec1a2423f04","date":"Apr 20, 2020","link":"https://www.businesswire.com/news/home/20200419005001/en/FDA-Grants-NEXUS%E2%84%A2-Aortic-Arch-Stent-Graft","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"eGn7ndUoR0KJll98bLWGlp5Zf738oItPJ3wFEf7EM863ivnLHL8R9H","news_summary":"FDA Grants NEXUS™ Aortic Arch Stent Graft System Breakthrough Designation","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"ca764d3f-2a95-465c-b756-47644438f90f","date":"Sep 15, 2019","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3770303,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"distribution deal, acquisition, stent graft company","company":"CyroLife","layoffs":null,"summary":"CyroLife, a NYSE-listed cardiac and vascular surgery company, has signed a distribution agreement and option agreement to acquire Israeli stent graft company EndoSpan. CyroLife will pay $10 million for European distribution rights and provide up to $15 million in debt financing. The option agreement allows CyroLife to acquire EndoSpan for $350 million plus up to an additional $100 million depending on the systems commercial success.","partners":["EndoSpan Ltd."],"customers":null,"investors":null,"confidence":9,"key_topics":["distribution deal","acquisition","stent graft systems","approval process","debt financing"],"date_of_event":"13.09.19","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment","Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment  #Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bimJ3yYRCWvzRybU2XDcNYAOKQbLltVbsEwdi4W0D6k3wnvK8HEysH","news_summary":"CyroLife Signs Option to Acquire EndoSpan for up to $450 Million","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ea8b75be-69dc-4815-9b11-0ff7d9d07334","date":"Sep 12, 2019","link":"https://www.businesswire.com/news/home/20190912005317/en/Endospan-Enters-Strategic-Distribution-Agreement-CryoLife","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"DVh5dNUO5zNb9nDHneEVcUaa82kreBNUDaW77wY5PjZ4XiThNYwIM9","news_summary":"Endospan Enters Into Strategic Distribution Agreement With CryoLife","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"bca57679-9f97-4008-9ef2-44c214058275","date":"Mar 20, 2019","link":"https://vascularnews.com/endospan-ce-mark-approval-nexus-aortic-arch-repair/","source":"vascularnews.com","visible":1,"analysis":{"tags":"medical technology","company":"Endospan","layoffs":null,"summary":"Endospan has received CE mark approval for its Nexus stent graft system, which is used for branched endovascular repair in the aortic arch. The approval allows specialists in Europe to perform standardized minimally invasive repair of the aortic arch. The Nexus stent graft system provides a ready-to-treat technology solution that reduces the need for open surgery and lengthy hospitalization periods. The system is designed to achieve a durable effective repair while minimizing the risk of stroke and other cardiovascular complications. Endospan plans to expand the availability of Nexus with a limited market release across Europe and continue evaluating its long-term safety and effectiveness.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Nexus stent graft","CE mark approval","Treatment of aortic arch pathology","Minimally invasive access","Cardiovascular specialists"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2LIxpABJNK7TWwN3d8hqKeP2Tr9NP9wCjWwPcITvAjQrhfqf7nlZJf","news_summary":"Endospan secures CE mark for Nexus stent graft system - Vascular News","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b3414cac-760c-409a-9178-577c12a4c371","date":"Feb 7, 2019","link":"https://vascularnews.com/nexus-aortic-arch-midterm-cacvs/","source":"vascularnews.com","visible":1,"analysis":{"tags":"medical devices","company":"EndoSpan","layoffs":null,"summary":"The article discusses the mid-term results of an investigational clinical study of the Nexus aortic arch stent graft system by EndoSpan. The study showed a 100% success rate in access, deployment, and procedural survival in 25 patients. The device demonstrated an excellent safety profile with no aneurysm-related deaths. The company expects to receive CE approval for the device in the first quarter of 2019. Longer-term data is needed to further study the performance of the Nexus stent graft system.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Nexus stent graft","clinical study","CE approval","safety profile","longer-term data"],"date_of_event":"2019-02-07","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Ffh4nNEXkgRjRBbFid0xPbXUgRDbQJA8TBNAhYVsYfnzODB2WPwaQZ","news_summary":"CE mark approval for Nexus aortic arch stent graft expected in Q1 2019 - Vascular News","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"cc6456f6-736b-427a-b750-3c80bd93f24a","date":"May 14, 2018","link":"https://www.businesswire.com/news/home/20180514005799/en/Endospan-Elects-Jeff-Elkins-Director","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Management Changes","company":"Endospan","layoffs":"NA","summary":"Endospan, an Israel-based medical device company, has announced the appointment of Jeff Elkins to its board of directors. Elkins has significant experience in the medical device industry, having served as President and CEO of Veniti Inc. since July 2015. He has also held various operations and product-development management positions at Cordis and Cordis Endovascular Systems, and Haemonetics Corp. during its IPO. Endospan is currently developing NEXUS, the first off-the-shelf endovascular approach to treating aortic arch disease.","partners":"NA","customers":"NA","investors":"NA","confidence":9,"key_topics":["Board Appointment","Aortic Arch Disease","Endovascular Repair","NEXUS Stent Graft System","Market Opportunity"],"date_of_event":"NA","valuation_amount":"NA","impact_on_company":"growth-positive","investment_amount":"NA","structured_issues":["Management Changes"],"acquisition_amount":"NA","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RjFrhWaeYpTT2SeLRUHlNPes0EJqWvYesyBgm9Jh5aODsxPdwlajDV","news_summary":"Endospan Elects Jeff Elkins as a Director","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8a48820b-ba4e-4757-ad3d-929cc0854473","date":"Mar 22, 2018","link":"https://www.tctmd.com/news/endospan-receives-ce-mark-horizontm-evar-system-based-robust-clinical-and-pivotal-data-treat","source":"www.tctmd.com","visible":1,"analysis":{"tags":"medical technology","company":"Endospan","layoffs":null,"summary":"Endospan, a pioneer in off-the-shelf EndoVascular Aortic Repair (EVAR), has received CE marking for its HORIZON Stent Graft System to treat Abdominal Aortic Aneurysm (AAA). The company is looking forward to working with potential partners to commercialize the HORIZON system for AAA repair.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["CE Mark","HORIZON EVAR System","Abdominal Aortic Aneurysm","EndoVascular Aortic Repair","CE marking"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WOM6cspwYUzOgnUfFbFujvTyW6MhEgjJBZ7tqJl7PkXYNcyg266Jez","news_summary":"Endospan Receives CE Mark for HORIZON™ EVAR System Based on Robust Clinical and Pivotal Data to Treat Abdominal Aortic Aneurysm (AAA)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0bc95792-b876-4eea-9a1a-fd6ca1e8528a","date":"Mar 12, 2018","link":"https://www.businesswire.com/news/home/20180312005590/en/Endospan-Appoints-Kevin-J.-Mayberry-CEO","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"pH5WLG2nheZuSHNnl5q1zIlPh2eZLwe04oYY2wVDpEuqhQ8viSR2qc","news_summary":"Endospan Appoints Kevin J. Mayberry as CEO","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"9e1d8bed-0f30-42df-a4ac-4f9baff0a780","date":"Oct 23, 2015","link":"http://www.geektime.com/2015/10/22/chinese-pharma-company-pumps-10-million-in-israeli-heart-tech/","source":"www.geektime.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"txWrz0v1eYcF68c7xuHIDSXsZznbocBLqT0ZOAQvkkAXlajSB7eu0J","news_summary":"http://www.geektime.com/2015/10/22/chinese-pharma-company-pumps-10-million-in-israeli-heart-tech/","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":13,"techcommunityinvolvement":null,"mediagallery":[{"id":"fc9cb1ff-663a-4718-9093-c4cb15f31b9e","timestamp":"2014-09-07 08:55:52.000000","resources_type":2,"resources_title":"Nexus","resources_file_name":"SmBS-y8dWM0","alt":"Nexus logo","imageurl":"https://img.youtube.com/vi/SmBS-y8dWM0/0.jpg","url":"http://youtu.be/SmBS-y8dWM0"},{"id":"bc3c2774-2a38-4689-9189-5f685ec9794f","timestamp":"2014-09-07 08:55:19.000000","resources_type":2,"resources_title":"Horizon","resources_file_name":"GDwCL3PAtWo","alt":"Horizon logo","imageurl":"https://img.youtube.com/vi/GDwCL3PAtWo/0.jpg","url":"http://youtu.be/GDwCL3PAtWo"}],"tags":["surgeons","vascular","medical-devices","cardiovascular","stent","surgery","cardiology"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Released","products":["NEXUS","HORIZON"],"geomarkets":["Europe"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":5,"lastfunding":"$25M","totalrounds":5,"fundingstage":"B","totalfunding":"$20M","publicinvestors":5,"lastpublicfunding":25000000,"totalpublicrounds":4,"totalpublicfunding":20000000},"team":[{"name":"Kevin Mayberry","email":"kevin@endospan.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoOHNjsEIDA","bounced":false,"claimed":0,"founder":0,"urlname":"kevin-mayberry","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg4a3azQoM","position":"CEO","last_name":"Mayberry","claimtoken":"pnihODn0vYIGCg1aYvDDZWQ0L4LEzs2nQj0KaU8MDGGEtE5eIaIU2y","first_name":"Kevin","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/kevin-mayberry-0977098/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-11-03 20:16:31.000000","initials":"KM","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Alon Shalev","email":"","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHf1oMJDA","bounced":false,"claimed":0,"founder":1,"urlname":"alon-shalev-2","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgkf76jgsM","position":"Founder","last_name":"Shalev","claimtoken":"ff57ddb1864d7959a341efc04ffe0022df4f04c8d2e5fa2910b8d8a243132aab","first_name":"Alon","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/alon-shalev-34608b42/","unsubscribed":false,"is_activeuser":1,"additionalemail":"alon@endospan.com","claimedemaildate":"2018-02-27 12:26:35.000000","initials":"AS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Rafi Benary","email":"","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgJ7FncoIDA","bounced":false,"claimed":0,"founder":1,"urlname":"rafi-benary-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICA7uOC4goM","position":"Co-Founder","last_name":"Benary","claimtoken":"692f223aa43bbe69e777cd31f8f818053d8166dbff8deb9c0e14fcf243a242ee","first_name":"Rafi","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/rafi-benary-4324704/","unsubscribed":false,"is_activeuser":0,"additionalemail":"rafi@endospan.com","claimedemaildate":"2018-09-26 08:41:20.000000","initials":"RB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Ami  Katz","email":"ami@endospan.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoM3asJgKDA","bounced":true,"claimed":0,"founder":0,"urlname":"ami-katz-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg7eybwQoM","position":"VP Operations & Engineering","last_name":"Katz","claimtoken":"BfytLwR5yabWQcg0wpjpIvqftMTNj5Gqn6NFgnB6Kpagfb5E04Hblx","first_name":"Ami ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/amikatz/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-11-03 20:16:33.000000","initials":"AK","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Asher Zilberstein","email":"asher@endospan.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Mro5dYLDA","bounced":true,"claimed":0,"founder":0,"urlname":"asher-zilberstein","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgioelxgsM","position":"VP QA/RA","last_name":"Zilberstein","claimtoken":"3LWtutVDPkX5XaOAG81nshXaOyw49NJkb5N3OOTwAr5mCagbgKjjcG","first_name":"Asher","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/asher-zilberstein-1a988621/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-11-03 20:16:50.000000","initials":"AZ","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Pieter  Buyl","email":"pieter@endospan.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4P6F3twIDA","bounced":true,"claimed":0,"founder":0,"urlname":"pieter-buyl","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgvuyLvAgM","position":"Vice President Sales & Marketing","last_name":"Buyl","claimtoken":"BSJDSxCsmzxchsWZBTA0B8kfOt6EaNuJk6cloPQl6BoetEhaL3OWbu","first_name":"Pieter ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/pieterbuyl/","unsubscribed":false,"is_activeuser":1,"additionalemail":"pieter@endospan","claimedemaildate":"2022-11-03 20:17:04.000000","initials":"PB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHD0KwIDA","fullname":"Sharon Shapira"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-05-26T00:00:00.000Z","crunchbaseid":"endospan","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Raz Zohar","creator_email":"raz@platterz.ca","createdate":"2014-09-07T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Sharon Shapira","affiliatedOrganizations":null,"timeline":[{"id":"9ebc25T0OfzrR4rcLiGmOvepzIjiO24m9VN306XHIeEpF2cC0VNIin","date":"Jul 2024","amount":"$25M","source":"https://www.prnewswire.co.uk/news-releases/endospan-receives-additional-25m-from-artivion-for-nexus-fda-approval-path-302188027.html","eventtype":"FundingRoundEvent","investment":[{"name":"Artivion","type":"Multinational","amount":null,"hidden":true,"country":"United States","fullurl":"/mnc_page/artivion","logokey":"$9DDfns6CI2KpZVqv1nG3FYgmo1hrVPYEQO2u9GvOhAXWA4cAMsLJiS.png","tagline":"Biological medical device company","urlname":"/mnc_page/artivion","isisraeli":0,"investorid":"KVziTnGc2Y7NdRHZIP5HvJVo4egldNHCaJKbgAG73UxJAELYLybQ5L","fundingtype":"Multinational","leadpartner":null,"investmentid":"baJ36kOFO5iPr63P7gQjPgvxRLcc68Z7pyKFUO7pVihq4QWBSVs3uj","fundingsubtype":null,"investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$9DDfns6CI2KpZVqv1nG3FYgmo1hrVPYEQO2u9GvOhAXWA4cAMsLJiS.png","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead&nbsp;","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Debt Financing","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":25000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"lAVGoq3y5QqgyDRiboasz3CjHk4OSJ6md6kMNwsXTRUyIlmfPkWwP8","date":"Sep 2019","amount":"$15M","source":"https://www.businesswire.com/news/home/20190912005317/en/Endospan-Enters-Strategic-Distribution-Agreement-CryoLife","eventtype":"FundingRoundEvent","investment":[{"name":"CryoLife","type":"Company","amount":null,"hidden":true,"country":"United States","fullurl":"/company_page/cryolife","logokey":"$FnjeUO0lr1bAeDJq69Zq0Dv9y8zQxkOVR8ZckhoT8uvH9IXmBMZPWH","tagline":"Cardiac and vascular surgery company","urlname":"/company_page/cryolife","isisraeli":0,"investorid":"SnjbbPjiqUMEgeD782X8pNlYrbK0DTLQnm9r3nvtpxmZf8IaQgA7Tx","fundingtype":"Company","leadpartner":null,"investmentid":"M25QjVY6avlnvsJO8tsNPkInd3856FAuK6RMeQC7b9bU9HgELb1m2i","fundingsubtype":null,"investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$FnjeUO0lr1bAeDJq69Zq0Dv9y8zQxkOVR8ZckhoT8uvH9IXmBMZPWH","leadcaption":"Lead&nbsp;","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Debt Financing","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":15000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"8cu5ofEvkEUFX35AmdDtrLxB2XwncLMjb7XovwqMuJtAsx5IzricEa","date":"Sep 2019","amount":"$10M","source":"https://www.businesswire.com/news/home/20190912005317/en/Endospan-Enters-Strategic-Distribution-Agreement-CryoLife","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":10000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCk8PPSCQw","date":"Oct 2015","amount":"$10M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Xizang Haisco Pharmaceutical Group","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/xizang-haisco-pharmaceutical-group","logokey":"$mPTTMPNX7inyYiw3bqFVyU8CS8oAXVUOCPC3QYinr6LxrLyk5gOExe","tagline":"","urlname":"/investor_page/xizang-haisco-pharmaceutical-group","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODkwIfcCQw","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"1564e4bc-e05d-4916-880e-6e8234a02132","fundingsubtype":"Corporate VC","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$mPTTMPNX7inyYiw3bqFVyU8CS8oAXVUOCPC3QYinr6LxrLyk5gOExe","leadcaption":"","followupcaption":""},{"name":"Accelmed","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/accelmed","logokey":"$FaEkBoI4nadGPZmOWfS9cEXuO0HvFoMp6AH9slrWmX4uk0dGvZ4xSj","tagline":null,"urlname":"/investor_page/accelmed","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKmI44gKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4443cff2-cd59-42c3-b5f6-42a483b5c370","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$FaEkBoI4nadGPZmOWfS9cEXuO0HvFoMp6AH9slrWmX4uk0dGvZ4xSj","leadcaption":"","followupcaption":""},{"name":"Sequoia Capital","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/sequoia-israel","logokey":"$X4XlkgDyQMSDU8pi8mipGGsgluWQCCZAaHNlpWtByvIgHPs5UXNb4w","tagline":null,"urlname":"/investor_page/sequoia-israel","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP74u9UKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"450bab3b-982d-4716-91c9-c1f99d934099","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$X4XlkgDyQMSDU8pi8mipGGsgluWQCCZAaHNlpWtByvIgHPs5UXNb4w","leadcaption":"","followupcaption":"Follow on&nbsp;"}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":10000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJC40ObTCgw","date":"Jan 2013","amount":"Undisclosed","source":"Crunchbase","eventtype":"FundingRoundEvent","investment":[{"name":"Sequoia Capital","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/sequoia-israel","logokey":"$X4XlkgDyQMSDU8pi8mipGGsgluWQCCZAaHNlpWtByvIgHPs5UXNb4w","tagline":null,"urlname":"/investor_page/sequoia-israel","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP74u9UKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"34cd9d25-73bf-4bfc-928d-f428b8a16da3","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Private","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$X4XlkgDyQMSDU8pi8mipGGsgluWQCCZAaHNlpWtByvIgHPs5UXNb4w","leadcaption":"","followupcaption":""}],"eventvisibility":"Private","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='<style>\n    .visibility-tooltip-container {\n        display: flex;\n        column-gap: 0.8rem;\n        padding: 0.8rem 1rem;\n        align-items: center;\n    } \n\n    .visibility-tooltip-container text {\n        font-size: 1.4rem;\n        text-transform: capitalize;\n        font-weight: 500;\n    }\n</style>\n\n<div class=\"visibility-tooltip-container\">\n    <img height=\"20\" width=\"20\" style=\"display: flex\" src=\"/assets/private-visibility.svg\"/>\n    <img height=\"20\" width=\"20\" style=\"display: none\" src=\"/assets/internal-visibility.svg\"/>\n    <text>Private</text>\n</div>'","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"8/2008","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"EndoSpan","logourl":"https://storage.googleapis.com/clean-finder-353810/$HRpWY90znSJ9krXJ77BglCFouu9thXgVbEpi4qHkyyhD9Yn36NglzE","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$HRpWY90znSJ9krXJ77BglCFouu9thXgVbEpi4qHkyyhD9Yn36NglzE","seoabout":"Endospan develops low-profile stent graft systems for treating aneurysms and dissections throughout the aorta, including infrarenal, visceral, and thoracic...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":6,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA>Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA/Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Medical Devices","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices","children":[{"title":"Medical Treatment & Therapeutics","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices>Medical Treatment & Therapeutics"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Providers","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]}]}],"coreTechnology":[]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Medical Devices","Medical Treatment & Therapeutics"],"coreTechnology":[],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Providers"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"9ebc25T0OfzrR4rcLiGmOvepzIjiO24m9VN306XHIeEpF2cC0VNIin","date":"Jul 2024","amount":"$25M","source":"https://www.prnewswire.co.uk/news-releases/endospan-receives-additional-25m-from-artivion-for-nexus-fda-approval-path-302188027.html","eventtype":"FundingRoundEvent","investment":[{"name":"Artivion","type":"Multinational","amount":null,"hidden":true,"country":"United States","fullurl":"/mnc_page/artivion","logokey":"$9DDfns6CI2KpZVqv1nG3FYgmo1hrVPYEQO2u9GvOhAXWA4cAMsLJiS.png","tagline":"Biological medical device company","urlname":"/mnc_page/artivion","isisraeli":0,"investorid":"KVziTnGc2Y7NdRHZIP5HvJVo4egldNHCaJKbgAG73UxJAELYLybQ5L","fundingtype":"Multinational","leadpartner":null,"investmentid":"baJ36kOFO5iPr63P7gQjPgvxRLcc68Z7pyKFUO7pVihq4QWBSVs3uj","fundingsubtype":null,"investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$9DDfns6CI2KpZVqv1nG3FYgmo1hrVPYEQO2u9GvOhAXWA4cAMsLJiS.png","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead&nbsp;","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Debt Financing","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":25000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"lAVGoq3y5QqgyDRiboasz3CjHk4OSJ6md6kMNwsXTRUyIlmfPkWwP8","date":"Sep 2019","amount":"$15M","source":"https://www.businesswire.com/news/home/20190912005317/en/Endospan-Enters-Strategic-Distribution-Agreement-CryoLife","eventtype":"FundingRoundEvent","investment":[{"name":"CryoLife","type":"Company","amount":null,"hidden":true,"country":"United States","fullurl":"/company_page/cryolife","logokey":"$FnjeUO0lr1bAeDJq69Zq0Dv9y8zQxkOVR8ZckhoT8uvH9IXmBMZPWH","tagline":"Cardiac and vascular surgery company","urlname":"/company_page/cryolife","isisraeli":0,"investorid":"SnjbbPjiqUMEgeD782X8pNlYrbK0DTLQnm9r3nvtpxmZf8IaQgA7Tx","fundingtype":"Company","leadpartner":null,"investmentid":"M25QjVY6avlnvsJO8tsNPkInd3856FAuK6RMeQC7b9bU9HgELb1m2i","fundingsubtype":null,"investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$FnjeUO0lr1bAeDJq69Zq0Dv9y8zQxkOVR8ZckhoT8uvH9IXmBMZPWH","leadcaption":"Lead&nbsp;","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Debt Financing","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":15000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"8cu5ofEvkEUFX35AmdDtrLxB2XwncLMjb7XovwqMuJtAsx5IzricEa","date":"Sep 2019","amount":"$10M","source":"https://www.businesswire.com/news/home/20190912005317/en/Endospan-Enters-Strategic-Distribution-Agreement-CryoLife","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":10000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCk8PPSCQw","date":"Oct 2015","amount":"$10M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Xizang Haisco Pharmaceutical Group","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/xizang-haisco-pharmaceutical-group","logokey":"$mPTTMPNX7inyYiw3bqFVyU8CS8oAXVUOCPC3QYinr6LxrLyk5gOExe","tagline":"","urlname":"/investor_page/xizang-haisco-pharmaceutical-group","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODkwIfcCQw","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"1564e4bc-e05d-4916-880e-6e8234a02132","fundingsubtype":"Corporate VC","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$mPTTMPNX7inyYiw3bqFVyU8CS8oAXVUOCPC3QYinr6LxrLyk5gOExe","leadcaption":"","followupcaption":""},{"name":"Accelmed","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/accelmed","logokey":"$FaEkBoI4nadGPZmOWfS9cEXuO0HvFoMp6AH9slrWmX4uk0dGvZ4xSj","tagline":null,"urlname":"/investor_page/accelmed","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKmI44gKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4443cff2-cd59-42c3-b5f6-42a483b5c370","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$FaEkBoI4nadGPZmOWfS9cEXuO0HvFoMp6AH9slrWmX4uk0dGvZ4xSj","leadcaption":"","followupcaption":""},{"name":"Sequoia Capital","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/sequoia-israel","logokey":"$X4XlkgDyQMSDU8pi8mipGGsgluWQCCZAaHNlpWtByvIgHPs5UXNb4w","tagline":null,"urlname":"/investor_page/sequoia-israel","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP74u9UKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"450bab3b-982d-4716-91c9-c1f99d934099","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$X4XlkgDyQMSDU8pi8mipGGsgluWQCCZAaHNlpWtByvIgHPs5UXNb4w","leadcaption":"","followupcaption":"Follow on&nbsp;"}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":10000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJC40ObTCgw","date":"Jan 2013","amount":"Undisclosed","source":"Crunchbase","eventtype":"FundingRoundEvent","investment":[{"name":"Sequoia Capital","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/sequoia-israel","logokey":"$X4XlkgDyQMSDU8pi8mipGGsgluWQCCZAaHNlpWtByvIgHPs5UXNb4w","tagline":null,"urlname":"/investor_page/sequoia-israel","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP74u9UKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"34cd9d25-73bf-4bfc-928d-f428b8a16da3","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Private","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$X4XlkgDyQMSDU8pi8mipGGsgluWQCCZAaHNlpWtByvIgHPs5UXNb4w","leadcaption":"","followupcaption":""}],"eventvisibility":"Private","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='<style>\n    .visibility-tooltip-container {\n        display: flex;\n        column-gap: 0.8rem;\n        padding: 0.8rem 1rem;\n        align-items: center;\n    } \n\n    .visibility-tooltip-container text {\n        font-size: 1.4rem;\n        text-transform: capitalize;\n        font-weight: 500;\n    }\n</style>\n\n<div class=\"visibility-tooltip-container\">\n    <img height=\"20\" width=\"20\" style=\"display: flex\" src=\"/assets/private-visibility.svg\"/>\n    <img height=\"20\" width=\"20\" style=\"display: none\" src=\"/assets/internal-visibility.svg\"/>\n    <text>Private</text>\n</div>'","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}